[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behavior-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behavior-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,85,124,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100533930","attention-deficit-hyperactivity-disorder-100533930",false,"NCT06232226","Attention Deficit Hyperactivity Disorder","Addictions and Attention Deficit Disorder With or Without Hyperactivity","ADA","Inclusion Criteria :\n\n* Patients aged over 18 years\n* For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago\n* For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed\n* Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)\n* For patients who can actually benefit from MPH: who have not yet started taking MPH\n* Social security affiliates\n\nExclusion Criteria :\n\n* Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible\n* Presenting difficulties in reading or writing the French language making data collection impossible\n* Unable to commit to being available for the 2 visits planned as part of the cohort\n* Under guardianship or legal protection\n* Patients who have used psychoactive substances within 12 hours prior to their visit","ALL","18 Years","99 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.",[13,28,29],"Behavior Hyperactive","Behavior Disorders",[31,32,33,34,35,36,37],"Attention Deficit Disorder with Hyperactivity","Addictive disorders","Neuropsychology","Methylphenidate","Atomoxetine","Functional impairment","Symptoms","RECRUITING","2026-04-14",{"date":41,"type":42},"2026-04-17","ACTUAL",{"date":44,"type":42},"2024-04-11",{"date":46,"type":22},"2026-12-31",{"name":48,"class":49},"Nantes University Hospital","OTHER",3,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100452068","evaluating-personalized-therapeutics-clinic-ptc-on-drug-drug-interactions-and-drug-gene-interactions-100452068","NCT05166694","Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions","Evaluating the Effectiveness of a Personalized Therapeutics Clinic (PTC) Intervention on Drug-Drug Interactions (DDIs) and Drug-Gene Interactions (DGIs)","Inclusion Criteria:\n\n1. Adult participants cared for by a participating provider at University of Chicago Medical Center.\n2. Participants must be at least 18 years of age.\n3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information.\n\nExclusion Criteria for Participants\n\n1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation.\n2. Participation in another pharmacogenomic study.\n3. Participants who have previously received genotyping from another source.\n4. Inability to understand and give informed consent to participate.\n\nInclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.",{"count":59,"type":22},1300,[25],"The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Doctors leading this study will look for variations (differences) in your genes that may suggest that you are at greater risk of having side effects or a greater chance of benefiting from certain medications. Individuals in this study will participate for roughly 9 months.",[63,64,65,66,29],"Cancer","Advanced Cancer","Advanced Solid Tumor","Mental Health Issue",[68,69,70,71,72,73,74],"tumor","advanced cancer","advanced solid tumor","cancer medication","prescriptions","inhibitor drug","inducer drug","2026-03-02",{"date":77,"type":42},"2026-03-04",{"date":79,"type":42},"2022-11-30",{"date":81,"type":22},"2027-11-01",{"name":83,"class":49},"University of Chicago",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":107,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100540305","a-transdiagnostic-mentalization-based-intervention-for-parents-with-mental-disorders-100540305","NCT06315114","A Transdiagnostic Mentalization-based Intervention for Parents With Mental Disorders","A Transdiagnostic Mentalization-based Intervention (LIGHTHOUSE Parenting Program) Versus Care as Usual for Parents With Mental Disorders in Adult Mental Health Service: a Randomised Clinical Trial","LIGHTHOUSE","Inclusion Criteria exclusive to the Outpatient Clinic\n\n* Age \\>18 years\n* Seeking treatment for one of the following non-psychotic disorders according to ICD-10: obsessive-compulsive disorder and anxiety disorders (F40-42), posttraumatic stress disorder (DF43), personality disorders (F60-61), or one of the previous disorders and a drug-or alcohol related disorder (F10-19) (i.e. 'dual diagnosis disorder')\n\nInclusion Criteria exclusive to the trial:\n\n* Parent of at least one child aged 0-17 years of age at baseline\n* Fluent i.e., sufficient Danish language skills\n* Parent is living with child or is in regular contact (min. 5 days monthly)\n* Written informed consent\n\nExclusion Criteria exclusive to the Outpatient Clinic:\n\n* Possibility of a learning disability (IQ\\\u003C75)\n* A diagnosis of schizotypal personality disorder or antisocial personality disorder\n* Presence of a comorbid psychiatric disorder that requires specialist treatment elsewhere\n* Concurrent psychotherapeutic treatment outside the clinic\n\nExclusion Criteria exclusive to the trial:\n\n* Acute suicidal risk or state of crises\n* Lack of informed consent\n* Acute child endangerment\n* Participation in another parenting focused intervention simultaniously","65 Years",{"count":95,"type":22},170,[25],"The aim of this randomised clinical trial is to evaluate the short and longterm effects of a transdiagnostic mentalization-based intervention (Lighthouse MBT Parenting Program) compared to care as usal (CAU) for parents with a mental disorder in adult mental health service.",[99,29,100,101,102,103,104,105,106],"Mental Disorder","Diagnosis, Psychiatric","Diagnosis Dual","Severe Mental Disorder","Mental Illness","Psychiatric Disorder","Psychiatric Disease","Psychiatric Illness",[108,109,110,111,112,113],"Mental disorder","Parent","Child","Preventive intervention","Prevention","Intergenerational transmission","2025-05-09",{"date":116,"type":42},"2025-05-14",{"date":118,"type":42},"2024-03-11",{"date":120,"type":22},"2028-04-01",{"name":122,"class":49},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100478471","evaluation-of-safe-use-of-securidrap-selfia-100478471","NCT05510401","Evaluation of Safe Use of SECURIDRAP® SELFIA®","Multicenter Clinical Investigation for the Evaluation of Safe Use of SECURIDRAP® SELFIA®","SECURIDRAP","Inclusion Criteria:\n\n* Patient at least 18 years old\n* Patient having a medical prescription for SÉCURIDRAP® SELFIA®\n* Patient in phase or state of disorientation\n* Patient with nocturnal behavior disordre\n* Patient with major cognitive impairment\n* Patient at risk of falling into bed\n* Patient subject to guardianship or curatorship\n* Patient beneficiary or affiliated to a social security scheme\n* Patient who has given their participation agreement aand informed consent\n\nExclusion Criteria:\n\n* Patient and\u002For guardianship or curatorship refusing to agree to participate in the clinical investigation\n* Patient in psychiatry\n* Patient with severe agitation\n* Patient who will be agitated once installed in the SÉCURIDRAP® SELFIA®\n* Patient with intolerance to the medical device\n* Patient able to extract himself from SÉCURIDRAP® SELFIA®\n* Patient able to unlock the bed rails by himself\n* Patient without social coverage or not benefiting from it through a third party\n* Patient minor, pregnant woman, persons deprived of their liberty\n* Patient who participating or having participated in another clinical investigation, drug or medical device in the 30 days preceding inclusion",{"count":133,"type":22},108,[25],"Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events likend to its use.\n\nFollowing the withdrawal from the market of the first version of the SECURIDRAP® SELFIA®, this clinical investigation is being carried out at the request and on the recommandation of the ASNM in order to assess the safety of the second version of the SECURIDRAP® SELFIA® coating.",[137,138,29],"Disorientation","Cognitive Impairment",[140,141,142],"disorientation","nocturnal behavioral disorders","major cognitive impairment","2024-11-19",{"date":145,"type":42},"2024-11-20",{"date":147,"type":42},"2022-05-18",{"date":149,"type":22},"2025-07-30",{"name":151,"class":152},"Groupe Mulliez-Flory","INDUSTRY",10,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":84},"100557257","impact-and-influence-of-the-use-of-hypnosis-adapted-to-people-with-severe-stage-neurocognitive-disorder-hapness-on-the-professional-practices-of-ehpad-establishment-for-dependent-elderly-people-caregivers-with-elderly-residents-100557257","NCT06535763","Impact and Influence of the Use of Hypnosis Adapted to People With Severe Stage Neurocognitive Disorder (HAPNeSS) on the Professional Practices of EHPAD (Establishment for Dependent Elderly People) Caregivers With Elderly Residents","HAPNeSS-E","Inclusion Criteria:\n\nEHPAD staff meeting the following criteria will be included in the study:\n\n* Nurses, care assistants, gerontological care assistants, psychologists, coordinating physicians, psychomotor therapists, occupational therapists;\n* More than one year's experience in the structure.\n\nThe study will examine the individual perceptions of EHPAD professionals of patients meeting the following criteria:\n\n* Be a resident of an EHPAD ;\n* suffering from a moderately severe or severe major neurocognitive disorder;\n* over 75 years of age.\n\nExclusion Criteria:\n\nEHPAD professionals will not be included:\n\n* Not fluent in French,\n* Not wishing to be trained in hypnosis.\n\nThe individual perception of EHPAD professionals of patients meeting these criteria will not be questioned in the study:\n\n* Minor neurocognitive impairment, major neurocognitive impairment at a mild or moderate stage, or no cognitive impairment;\n* under 75 years of age.",true,{"count":163,"type":22},36,"OBSERVATIONAL","The aim of this study is to propose a non-anxiety-inducing method of managing behavioral disorders for patients and healthcare professionals. The main objective of this study is to evaluate the implementation, use and effects of HAPNeSS (Hypnosis Adapted to People with Severe Neurocognitive Disorders) training on the management of residents aged over 75 with moderately severe to severe Alzheimer's disease or a related disorder, who may present behavioral disorders, with caregivers working in EHPAD.",[167,29],"Alzheimer Disease",[169,170,171],"self-hypnosis","formation","seniors","NOT_YET_RECRUITING","2024-08-01",{"date":175,"type":42},"2024-08-02",{"date":177,"type":22},"2024-09",{"date":179,"type":22},"2025-03",{"name":181,"class":49},"University Hospital, Bordeaux"]